Sulfasalazine for rheumatoid arthritis

Area of Science:

• Rheumatology
• Pharmacology
• Clinical Trials

Background:

• Rheumatoid arthritis (RA) is a chronic autoimmune disease causing joint inflammation and pain.
• Sulfasalazine is a disease-modifying antirheumatic drug (DMARD) used in RA treatment.
• Short-term efficacy and toxicity data for sulfasalazine in RA require synthesis.

Purpose of the Study:

• To evaluate the short-term efficacy of sulfasalazine in treating rheumatoid arthritis.
• To assess the toxicity profile of sulfasalazine in RA patients.

Main Methods:

• Systematic review and meta-analysis of randomized controlled trials (RCTs) and controlled clinical trials (CCTs).
• Searched Cochrane Musculoskeletal Group trials register, Medline, and contacted experts for relevant studies up to July 1997.
• Included 6 trials with 468 patients comparing sulfasalazine to placebo, assessing joint counts, pain, ESR, and withdrawals due to adverse reactions.

Main Results:

• Sulfasalazine demonstrated statistically significant benefits in reducing tender and swollen joint scores (SMD -0.49), pain (SMD -0.42), and erythrocyte sedimentation rate (WMD -17.6mm) compared to placebo.
• Withdrawals due to adverse reactions were significantly higher in the sulfasalazine group (OR=3.0).
• Patients on placebo were more likely to discontinue due to lack of efficacy.

Conclusions:

• Sulfasalazine offers clinically and statistically significant improvements in rheumatoid arthritis disease activity.
• The drug's impact on overall health status and radiological progression remains unclear but appears modest.
• Increased adverse reactions necessitate careful consideration of sulfasalazine use in RA management.